Cristiana Pires

Cristiana Pires is one of the co-founders of Asgard Therapeutics and serves as CEO since the start of the company. Cristiana performed her post-doctoral studies in Filipe Pereira’s lab pioneering dendritic cell reprogramming technologies, that opened avenues to applying it to modulate immune responses and led to the creation of Asgard Therapeutics. Before that, Cristiana trained in pharmaceutical sciences and performed her PhD exploring direct reprogramming for cell replacement therapy applications. As CEO, Cristiana has attracted non-dilutive funding, including competitive Horizon Eurostars and Novo Nordisk Foundation grants as well as a €6M seed round from seasoned investors. Cristiana manages a team of 9 FTEs, with solid experience in reprogramming, pharmacology and gene therapy, that achieved extensive proof-of-concept for the in-vivo reprogramming approach using ex-vivo translational and in vivo models, as well as selected the lead program delivery platform. Cristiana is now worki